AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04210752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2 (EG-HZ-002)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Study NCT04210752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3 (EG-HZ-003)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Study NCT03319602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double trunk mask add above a nasal canulae
Description: oxygenation only with nostril prongs
Study NCT03319602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double trunk mask add above a nasal canulae
Description: oxygenation only with nostril prongs
Study NCT04472962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-exercise meal
Description: Mixed meal with low-carbohydrate-high-protein content
Study NCT04472962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-exercise meal
Description: Mixed meal with high-carbohydrate-low-protein content
Study NCT01512758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets
Study NCT01934842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C
Study NCT01934842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAFE-T-FILL
Study NCT03237910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMSA
Description: A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
Study NCT03237910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Defibrillation
Description: delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
Study NCT03237910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation
Description: delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
Study NCT03237910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR
Description: chest compressions and ventilations at a rate of 30:2
Study NCT03237910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPR
Description: chest compressions and ventilations at a rate of 30:2
Study NCT01347359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one peer support
Description: The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
Study NCT01347359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program).
Study NCT01979250 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DSAEK surgery
Description: Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
Study NCT04898452 — intervention group
Intervention type: OTHER
Intervention: A new model of interaction across health services with use of welfare technology and telemedicine
Description: Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
Study NCT06128486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens
Description: Vision Correction
Study NCT00956072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: Patients receive imatinib mesylate
Study NCT00956072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study NCT03091179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: active nasal oxygen delivery system
Study NCT03091179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: a plastic tube for mechanical ventilation
Study NCT03723356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Siemens Biograph mMR (molecular MR)
Description: 5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
Study NCT03723356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
Study NCT03723356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion Spectrum Imaging (DSI)
Description: DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
Study NCT04210752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 4 (EG-HZ-004)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Study NCT04210752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 5
Description: Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection
Study NCT04842539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
Study NCT04842539 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Nutritional supplementation and other supportive measures as per standard guidelines
Study NCT02598180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VergenixTM Flowable Gel
Description: The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
Study NCT01782014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy using different methods of insufflation
Study NCT01782014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy using different methods of insufflation
Study NCT04264325 — intervention group
Intervention type: OTHER
Intervention: diaphragmatic ultrasound measure
Description: patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
Study NCT04791917 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Concentric Biceps Flexion
Description: Muscle shortening biceps exercise
Study NCT01610492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 10mg/kg administered intravenously
Study NCT03315078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
Description: Administered by intravenous (IV) infusion
Study NCT03315078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Administered by IV infusion at a dose of 60 mg/kg/day
Study NCT03315078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered by IV infusion at a dose of approximately 3 mg/kg per day
Study NCT04071834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Detection of blood orphanin and norepinephrine in patients
Study NCT04292444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
Study NCT04292444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
Study NCT01964079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Study NCT01964079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Study NCT03138408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-004
Description: Intravenous
Study NCT03138408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous
Study NCT02784145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resistant starch
Study NCT02784145 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recommendation with regard to nutrition
Description: Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
Study NCT04534699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: KBP-5074 tablet
Study NCT00139360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Anti angiogenesis treatment
Study NCT03340090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Hemopatch-PEG-coated collagen patch
Description: Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
Study NCT03314909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
Study NCT03314909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
Study NCT03573375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
Study NCT01027455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device
Description: Humidified warm carbon dioxide gas insufflation during laparosopic procedure
Study NCT01027455 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Appendicectomy
Description: Dry and Cold carbon dioxide gas insufflation
Study NCT01027455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendicectomy
Description: Humidified warm carbon dioxide gas insufflation during laparosopic procedure
Study NCT03121417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg given IV
Study NCT01171950 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CentriMag Ventricular Assist System
Description: All patients will be treated with the CentriMag device for up to 30 days.
Study NCT02836431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1mcg Intravenous
Description: DEX 1 mcg/kg Intravenously
Study NCT03314909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HP-HD
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
Study NCT05237778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
Study NCT05237778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery Rehearsal Therapy
Description: These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
Study NCT03114384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creation and detection of patient-respirator asynchronies
Description: The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
Study NCT02658773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-Prilocaine cream
Study NCT02658773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Study NCT00600899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h
Description: Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
Study NCT00600899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h
Description: Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
Study NCT05111028 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Room Temperature stored Platelet transfusion
Description: An autologous transfusion of platelets stored at 22°C for 7 days.
Study NCT05111028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Room Temperature stored Platelet transfusion
Description: An autologous transfusion of platelets stored at 22°C for 7 days.
Study NCT05111028 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Cold Stored Platelet transfusion
Description: An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
Study NCT05111028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cold Stored Platelet transfusion
Description: An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
Study NCT02822261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66_R84-088)
Study NCT04354883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Chest Compressions on Manikin in Underwater Setting
Description: Two different methods of CPR in an analogue model of mircogravity
Study NCT01745042 — intervention group
Intervention type: OTHER
Intervention: Clinical exams
Description: Physiological and biochemical tests; quality of life questionnaire; body composition measurement
Study NCT01122849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Nasal Dilator
Description: Prototype nasal dilator AB2R11
Study NCT01122849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nasal Strip
Description: Breathe Right Nasal Strip- Clear small/medium
Study NCT01122849 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Strip
Description: Placebo strip
Study NCT01569048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine
Description: Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
Study NCT01569048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
Study NCT01846741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: M106 VNS Therapy System
Study NCT01853878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
Description: Intramuscular administration
Study NCT01853878 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study NCT04020497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ensemble programme
Description: Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
Study NCT04020497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAU
Description: Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team.
Study NCT04020497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Description: Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team.